Hybio Pharmaceutical Co., Ltd.
300199
Rang în acțiuni
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Preț acțiune
$3.69
Capitalizare de piață
$3.11B
Schimbare (1 zi)
-7.75%
Schimbare (1 an)
21.56%
Țară
CN
Tranzacționează Hybio Pharmaceutical Co., Ltd. (300199)
Categorie
Healthcare
Venituri pentru Hybio Pharmaceutical Co., Ltd. (300199)
Venituri în Jun 2026 TTM: $165.50M
Conform celor mai recente rapoarte financiare ale Hybio Pharmaceutical Co., Ltd., venitul actual al companiei (TTM) este $165.50M. În anul 2024, compania a avut un venit de $80.86M o creștere față de venitul din anul 2023, care a fost de $60.94M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Hybio Pharmaceutical Co., Ltd. din 2007 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $165.50M | 19.82% |
| 2025 | $138.12M | 70.82% |
| 2024 | $80.86M | 32.68% |
| 2023 | $60.94M | -40.32% |
| 2022 | $102.11M | -11.82% |
| 2021 | $115.79M | 4.81% |
| 2020 | $110.48M | 25.25% |
| 2019 | $88.20M | -52.02% |
| 2018 | $183.82M | -4.03% |
| 2017 | $191.55M | 55.53% |
| 2016 | $123.15M | 4.10% |
| 2015 | $118.31M | 74.71% |
| 2014 | $67.72M | 36.28% |
| 2013 | $49.69M | 38.99% |
| 2012 | $35.75M | 38.27% |
| 2011 | $25.86M | 39.97% |
| 2010 | $18.47M | 36.03% |
| 2009 | $13.58M | 19.78% |
| 2008 | $11.34M | 47.29% |
| 2007 | $7.70M | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $23.54B | 14,121.00% |
DE
|
|
| $23.73B | 14,241.61% |
DE
|
|
| $29.24B | 17,567.76% |
JP
|
|
| $5.85B | 3,434.05% |
CH
|
|
| $6.61B | 3,895.03% |
IN
|
